Sensitive Nanozyme Test May Provide Rapid Point-of-Care Diagnosis of Ebola
|
By LabMedica International staff writers Posted on 24 Sep 2015 |

Image: In the new nanozyme immunochromatographic strip test for Ebolavirus (EBOV), the magnetic (A) and catalytic (B) properties of the nanozymes (Fe3O4 magnetic nanoparticles (MNPs)) make the signal 100 times stronger than standard strips with colloidal-gold nanoparticles, generating a deeper color reaction that can be more clearly seen by the naked eye (Image courtesy of Duan D et al., 2015, and Elsevier).
Researchers have developed a simple low-cost Ebolavirus (EBOV) test based on detection technology using magnetic nanoparticles that has shown 100x higher sensitivity than the standard immunochromatographic ELISA gold strip test.
In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.
Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.
“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.
The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.
“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”
The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.
Related Links:
Chinese Academy of Sciences
Elsevier
In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.
Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.
“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.
The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.
“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”
The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.
Related Links:
Chinese Academy of Sciences
Elsevier
Latest Microbiology News
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Channels
Clinical Chemistry
view channel
Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
Primary central nervous system lymphoma (PCNSL) is a rare malignancy of the brain, spinal cord, and eyes with delayed diagnosis and poor outcomes. Current fluid-based testing using interleukin measurements... Read more
New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage and remains one of the most lethal solid tumors. Clinicians commonly use serum carbohydrate antigen 19-9 (CA19-9) to... Read moreMolecular Diagnostics
view channel
Gene Fusion Patterns May Flag High Risk Solitary Fibrous Tumors
Solitary fibrous tumor (SFT) is a rare subtype of sarcoma, a cancer that develops in connective tissues such as fat, muscle, blood vessels, and fibrous tissue. SFTs most commonly arise in the chest cavity... Read more
New RNA Origami Method Supports Faster Targeted Testing for Repeat Expansion Disorders
Repeat expansion disorders drive conditions such as myotonic dystrophy, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), yet accurately sizing the mutated sequences remains difficult.... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read morePathology
view channel
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read moreTechnology
view channel
AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read moreIndustry
view channel
Natera to Present Data on MRD-Guided Cancer Care at ASCO 2026
Natera, Inc. (Austin, TX, USA), a company focused on cell-free DNA testing and precision medicine, announced an oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting,... Read more








